Pharma Stocks

On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the “most consequential executive order” in U.S. history, aimed at lowering prescription drug prices. What Happened: Trump said the executive order, set to be signed at 9 a.m. Monday, will...

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volatility. With President Donald Trump’s administration rehashing contentious ideas on drug...

U.S. President Donald Trump has announced his intention to impose a 25% tariff on auto imports, alongside chips and pharmaceuticals, causing a stir in international trade. What Happened: Trump disclosed on Tuesday his plan to implement auto tariffs “in the neighborhood of 25%”....

Shares of Caballeta Bio Inc (NASDAQ:CABA) rose by 24.38% to $3.01 apiece on Wednesday and advanced by 4.65% to $3.15 per share in after-hours trading, following an update on their Systemic Sclerosis drug trial. Also read: Trump’s Tariff Threat To Canada May Disrupt Oil Markets, Inflate...

The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical questions about the future of the cannabis industry, especially if cannabis is federally legalized. The...

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and...

It's been a quiet week in the markets, marked by a dearth of major economic news and a consistent flow of positive indicators from the first-quarter earnings season. As of May 7, 424 companies in the S&P 500 have disclosed their earnings, with 78% surpassing earnings expectations and 61%...

Pipeline and regulatory updates continue to be in focus in the biotech sector. While nothing much came out of bigwigs apart from a few, shares of clinical-stage biotechs like Disc Medicine, Inc. (NASDAQ: IRON) and Verve Therapeutics (NASDAQ: VERV) plunged on disappointing updates. Recap of the Week...

Retail traders have been observed to be selling off their shares in the ‘Magnificent Seven’ tech stocks, with a noticeable shift towards pharmaceutical stocks, according to a recent report by JPMorgan. What Happened: Retail traders have been net sellers of the majority of the ‘...

Pharmaceutical company Merck & Company (NYSE: MRK) reports second quarter financial results before market open Tuesday. After being one of the 15 Dow Jones component stocks that traded higher in the first half of 2023, investors now see the stock down year-to-date. Here’s a look at the...

One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug Company, which announced a new initiative Thursday. What Happened: Cuban launched the Mark Cuban Cost...

Prominent market commentator Jim Cramer believes defaulting on the national debt could change the geopolitical face of the United States as the debt ceiling impasse continues although the White House has reportedly acknowledged some spending cuts may be required. "I hated being so downbeat tonight...

Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases. "We are enthusiastic about the potential of [our] strategy to hopefully bring much-needed therapies to patients that wouldn’t otherwise have them," he...

Jim Simons is the founder and hedge fund manager of Renaissance Technologies, which currently has a total portfolio value north of $77 billion, per Stock Circle. This hedge fund uses a quantitative strategy in determining its stock trades. Simons' quantitative approach has had legendary success...

Microvast Holdings Inc. (NASDAQ: MVST) remains the most-discussed stock on Reddit’s r/WallStreetBets forum as of Tuesday night, while AMC Entertainment Holdings Inc. (NYSE: AMC), Moderna Inc. (NASDAQ: MRNA) and Clover Health Investments Corp. (NASDAQ: CLOV) are also seeing high interest. What...